Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study on the behalf of G2I and IFM.
Fiche publication
Date publication
mars 2024
Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Dr SONNTAG Cécile
Tous les auteurs :
Jourdes A, Cellerin E, Touzeau C, Harel S, Denis B, Escure G, Faure E, Jamard S, Danion F, Sonntag C, Ader F, Karlin L, Soueges S, Cazelles C, de La Porte des Vaux C, Frenzel L, Lanternier F, Brousse X, Cazaubiel T, Berger P, Collignon A, Blot M, Pieragostini A, Charles M, Chaleteix C, Redor A, Roland V, Cartau T, Macro M, Chalopin T, Vallet N, Perrot A, Martin-Blondel G,
Lien Pubmed
Résumé
Bispecific antibodies (BsAbs) are an effective treatment used in relapsed/refractory multiple myeloma. Despite a well-tolerated safety profile, infectious events appeared to be frequent in clinical trials. Real-world data on epidemiology, characteristics, risk factors and outcomes of infections in patients treated with BsAb are still needed.
Mots clés
Adverse event, Bispecific antibodies, Epidemiology, Infections, Multicentric, Multiple myeloma, Retrospective
Référence
Clin Microbiol Infect. 2024 03 1;: